Treatment of Gastric and Gastroesophageal Cancers—Do We Really Need Anthracyclines?
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2016.3064
Abstract: Combination chemotherapy has been shown to be superior to single-agent therapy in gastric and gastroesophageal cancers. However, there is no consensus regarding the optimal regimen. Epirubicin-containing regimens are considered standard in parts of Europe, but… read more here.
Keywords: treatment gastric; anthracyclines treatment; gastroesophageal; gastric gastroesophageal ... See more keywords
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer communications"
DOI: 10.1002/cac2.12214
Abstract: BACKGROUND Current treatment options for human epidermal growth factor receptor 2 (HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit. Further, there is no specific treatment for HER2 immunohistochemistry (IHC) 2+ and fluorescence in-situ… read more here.
Keywords: patients her2; her2 overexpressing; junction cancer; gastroesophageal junction ... See more keywords
PD‐L1 expression in gastric and gastroesophageal junction cancer patients treated with perioperative chemotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.26929
Abstract: The incidence, predictive, and prognostic impact of programmed cell death (PD‐L1) expression in gastric (GC) and gastroesophageal junction tumors (GEJC) treated with perioperative chemotherapy is poorly understood. We aimed to assess PD‐L1 expression by immunohistochemistry… read more here.
Keywords: treated perioperative; gastroesophageal junction; expression; perioperative chemotherapy ... See more keywords
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Sign Up to like & getrecommendations! Published in 2018 at "Gastric Cancer"
DOI: 10.1007/s10120-018-00909-5
Abstract: BackgroundThe multicohort, phase II, nonrandomized KEYNOTE-059 study evaluated pembrolizumab ± chemotherapy in advanced gastric/gastroesophageal junction cancer. Results from cohorts 2 and 3, evaluating first-line therapy, are presented.MethodsPatients ≥ 18 years old had previously untreated recurrent or metastatic gastric/gastroesophageal junction… read more here.
Keywords: therapy; combination; gastroesophageal junction; gastric gastroesophageal ... See more keywords
AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study
Sign Up to like & getrecommendations! Published in 2021 at "Acta Oncologica"
DOI: 10.1080/0284186x.2021.1912822
Abstract: Abstract Purpose Gastric cancer is the fifth most common neoplasm worldwide with high rates of mortality. Afatinib, a low molecular, irreversible potent inhibitor of ErbB trans-membrane receptor family, has shown promising results according to preclinical… read more here.
Keywords: gastric gastroesophageal; efficacy; gastroesophageal junction; first line ... See more keywords
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003635
Abstract: Immune checkpoint inhibitors have greatly improved the prognoses of diverse advanced malignancies, including gastric and gastroesophageal junction (G/GEJ) cancer. However, the role of anti-programmed cell death protein-1 treatment in the neoadjuvant setting remains unclear. This… read more here.
Keywords: safety; advanced resectable; sintilimab; gastroesophageal junction ... See more keywords
ctDNA in Gastric and Gastroesophageal Cancer: Prognostic, Predictive, or Preliminary?
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-2774
Abstract: In gastric and gastroesophageal adenocarcinoma, circulating tumor DNA identifies molecular drivers missed using routine tumor biopsy, can refine patient selection for targeted therapy, and may be prognostic following surgical resection. However, lack of standardization could… read more here.
Keywords: ctdna gastric; gastric gastroesophageal; cancer prognostic; gastroesophageal ... See more keywords
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-4021
Abstract: Abstract Purpose: To compare napabucasin (generator of reactive oxygen species) plus paclitaxel with paclitaxel only in patients with second-line advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Patients and Methods: In the double-blind, phase III BRIGHTER… read more here.
Keywords: advanced gastric; gastroesophageal junction; placebo; plus paclitaxel ... See more keywords
Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers: Results from the FAST study.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.4038
Abstract: 4038Background: Claudin 18.2 (CLDN18.2), a gastric mucosa tight junction protein, is aberrantly expressed in various cancers. In the FAST Phase 2 trial (NCT01630083), IMAB362, an anti-CLDN18.2 mono... read more here.
Keywords: claudin; claudin her2; expression claudin; junction ... See more keywords
Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e16585
Abstract: e16585Background: Envafolimab is a novel fusion protein of humanized anti-PD-L1 single domain antibody and human IgG1 Fc, formulated for subcutaneously (SC) injection. This study examined the feasi... read more here.
Keywords: plus chemotherapy; advanced gastric; chemotherapy advanced; gastroesophageal junction ... See more keywords
Comprehensive evaluation of genomic alterations in patients with gastric and gastroesophageal adenocarcinoma stratified according to TP53 mutation status.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.3_suppl.238
Abstract: 238Background: Gastric (GC) and gastroesophageal adenocarcinomas (GEA) are molecularly diverse. Molecular biomarkers of clinical significance have been identified that impact treatment decision mak... read more here.
Keywords: genomic alterations; gastric gastroesophageal; evaluation genomic; patients gastric ... See more keywords